Follicle-stimulating hormone (FSH), produced by pituitary gonadotrope cells, is required for maturation of ovarian follicles. The FSHb subunit is the limiting factor for production of mature hormone and provides biological specificity. Activin dramatically induces FSHb transcription and the secondary rise in FSH, important for follicular development, is dependent on this induction. Thus, regulation of FSHb levels by activin is crucial for female reproductive fitness. This review discusses activin signaling pathways, transcription factors and FSHb promoter elements required for activin responsiveness. Because FoxL2, a forkhead transcription factor, was recently shown to be instrumental in relaying activin signaling to the FSHb promoter, we focus in this paper on its role and the inter-relatedness of several key players in activin responsiveness on the FSHb promoter.
Activin regulation of FSHb gene expression FSH is a dimeric glycoprotein hormone composed of a unique b subunit and a common a subunit shared with luteinizing hormone (LH) and thyroid-stimulating hormone. Low FSH levels prevent follicular growth, whereas high levels are associated with premature ovarian failure [1] . Female mice lacking FSHb exhibit an arrest in ovarian folliculogenesis and women with mutations in the FSHb gene are infertile [2] . The importance of appropriate regulation of FSH levels is also illustrated in FSHb transgenic mice, in which superovulation occurred without ovary depletion when the FSHb promoter was used to drive expression of the FSHb gene [3] . Therefore, these studies demonstrate that proper regulation of FSH levels is critical for female fertility.
Transcription of the FSHb gene is dynamically regulated during the estrous cycle. Changes in FSHb mRNA levels precede changes in FSH concentration in the circulation, strongly implying that FSHb transcription is the rate-limiting factor in the production of the mature hormone [4, 5] . Before the gonadotropin-releasing hormone (GnRH)-induced ovulatory surge in the afternoon of proestrus, FSHb mRNA levels increase fivefold concomitantly with LHb. Later, during estrus, transcription of FSHb again increases by threefold [4, 5] . A secondary increase of FSH also occurs during the human menstrual cycle at the end of the luteal phase and in the beginning of the follicular phase. This secondary FSH rise is necessary for follicular development and is dependent on activin [6, 7] . Notably, in female rats infused with follistatin, an inhibitor of activin, both FSHb mRNA and FSH levels in the blood can be reduced during the secondary rise [8] . Expression of both intrapituitary follistatin and ovarian inhibin fluctuate during the estrous cycle in opposition to the levels of FSHb mRNA [8] [9] [10] , suggesting that bioavailability of activin, through changes in follistatin and/or inhibin levels, is a crucial regulatory component of FSHb synthesis.
Activin is a potent regulator of FSHb gene expression and was originally identified as a component of ovarian follicular fluid that increased FSHb synthesis and FSH secretion from pituitary gonadotrope cells [11] [12] [13] . Although activin was known for many years to regulate FSH production, it was not until the discovery that FSHb was synthesized by the gonadotrope-derived LbT2 cell line that the molecular mechanisms of activin induction could begin to be elucidated [14] . In this review, we focus our attention on activin regulation of the FSHb promoter including recent advances in our understanding of activin-related signal transduction mechanisms. This is timely because novel players, not previously associated with activin signaling pathways, have recently come to light.
Activin signaling via Smad proteins
Activin signaling in gonadotrope cells through type II activin receptors (ActRII A/B) and type I receptors [activin receptor-like kinases (ALK) 4/7] (Box 1), results in the phosphorylation of receptor-associated Smad proteins, Smad2 and Smad3 (Figure 1 ) [15] [16] [17] . Upon phosphorylation, Smad2/3 bind to Smad4 and translocate into the nucleus of gonadotrope cells [15] . Once in the nucleus, Smad proteins can induce or repress gene expression as a heterodimer or in combination with other transcription factors. Smad3/4 can bind DNA directly through a defined Smad-binding element (SBE) (GTCTAG[N]C) or a Smad half site (GTCT). Smad2 and/or Smad3 have also been shown to interact with transcription factors such as activator protein (AP)-1 [18] , forkhead activin signal transducer-1 [19] , FoxO [20] and steroid receptors [21] [22] [23] [24] .
Although it is evident that Smad-dependent signaling is necessary for activin induction of FSHb in rodents, it is still unclear whether Smads play a role in other mammalian species. The evidence thus far suggests that species-specific differences in the FSHb promoter result in greater or lesser sensitivity to transcriptional regulation by Smad proteins [25, 26] however, use of dominant negative (DN) Smads has produced inconsistent results. Overexpression of DN Smad2 reduces activin induction of murine FSHb mRNA in LbT2 cells [16] and a DN Smad3 lacking the Cterminal tail reduced activin induction of rat FSHb [30] . By contrast, a DN Smad3 with mutated phosphorylation sites had no effect on activin induction of the ovine FSHb gene [31] , suggesting a species-specific response to Smad-dependent signaling.
There is also some debate about the contributions of the various Smad proteins to activin induction in gonadotrope cells. Activin induction of murine FSH transcription requires Smad4 [32] . Overexpression of Smad3 and Smad4, but not Smad2, induces rat and murine FSHb gene expression [17, 30, 33] ; however, Smad2 overexpression was shown to be low in LbT2 cells [17, 34] . Interestingly, overexpression of a Smad2 isoform lacking exon 3 resulted in FSHb induction, whereas replacement of exon 3 of Smad3 with that of Smad2 rendered Smad3 incapable of being expressed in transient transfection experiments [17] . In contrast to the rodent promoters, Smad3 overexpression was shown to have a minimal effect on the ovine [31] and human FSHb promoters [25, 35] , which is probably a result of their lack of a consensus SBE that is present specifically in the rodent FSHb promoters. RNA interferencemediated knockdown of Smad2 and Smad3 was reported to reduce basal expression of the rodent FSHb gene [17, 34] . Because LbT2 cells express endogenous activin, it is unclear from these experiments whether basal gene expression is truly affected by Smads. Pretreatment with follistatin could help resolve this question. Several reports demonstrated that knockdown of Smad2 or Smad3 affects responsiveness of the rodent FSHb gene to activin or a constitutively active form of ALK4 [17, 35] . By contrast, another report saw no effect of Smad2 knockdown on activin induction of FSHb [34] . Although Smad2 might be dispensable for activin signaling in gonadotropes, the overall evidence indicates that Smad3 and Smad4 are necessary for induction of the rodent FSHb promoters. The necessity of Smad proteins for activin induction of other mammalian FSHb promoters remains to be investigated.
Smad-independent activin signaling via transforming growth factor-b activated kinase 1 and p38 kinases In addition to Smad proteins, activin signaling has been reported to result in the activation of Akt, extracellular signal-regulated protein kinase (ERK)1/2 and p38 signaling pathways in LbT2 cells and ovine primary pituitary cells [16] . Blockage of Akt signaling using a phosphoinositide 3-kinase (PI3K) inhibitor reduced the amount of Smad2 phosphorylated by activin. However, inhibition of Akt signaling did not alter activin induction of the ovine and murine FSHb genes, suggesting that this pathway is not necessary for activin responsiveness, at least in these species [16] . Inhibition of c-Jun N-terminal kinase (JNK) and ERK1/2 signaling pathways did not appear to alter activin signaling on rodent or ovine FSHb promoters [16, [29] [30] [31] . By contrast, the p38 mitogen-activated protein kinase (MAPK) appears to play a role in activin induction of FSHb gene expression because an inhibitor of p38 MAPK reduced FSHb mRNA expression. We and others have shown that treatment of LbT2 cells with inhibitors of p38 reduced activin signaling on ovine and murine FSHb promoters [28, 29, 31] , although one report did not see an
Box 1. Activin isoforms and activin receptors
Activin is a dimer of two b subunits. There are several b isoforms: bA, bB, bC and bE. bA and bB, which share 65% sequence identity but are differentially expressed, form dimers known to have physiological roles. Thus, activin A is a homodimer of bA subunits and activin B contains two bB subunits. bA and bB can also form heterodimers. Activin A is the predominant isoform expressed in the ovary, whereas gonadotropes express higher levels of activin B [51] . Activin B is also expressed throughout the pituitary [52] and in cultured pituitary cells [53] . Because activin is present at low levels in the blood, activin action in gonadotrope cells is considered to be predominantly paracrine or autocrine [54] . Both activin A and B can induce FSHb gene expression in immortalized gonadotrope cells [25] . Activin A binds to the type II receptor A (ActRIIA) on the surface of gonadotrope cells, which in turn results in the recruitment and phosphorylation of the type I receptor, ALK4. Activin B binds with higher affinity to ActRIIB receptors, which selectively recruit and activate ALK7 [55] [56] [57] . All of these receptors are expressed in pituitary gonadotrope cells [14, 54] . ALK4 and ALK7 are likely to be functionally interchangeable in gonadotrope cells, because both receptors phosphorylate Smad2 and Smad3 [58] , and the effects of constitutively active forms of these receptors map to the same regions of the FSHb promoter [25] . Because the levels of activin receptors remain relatively constant throughout the estrous cycle, modulation of activin signaling probably occurs as a result of changes in follistatin and/or inhibin levels and through interactions with other hormone signaling pathways (recently reviewed in [50] ).
[ ( F i g u r e _ 1 ) T D $ F I G ] effect [16] . Interestingly, the transforming growth factor-b activated kinase (TAK)1 inhibitor, 5Z-7-oxoaeanol, has been reported to block activin induction of ovine FSHb gene expression [31] . Overexpression of TAK1 along with its binding proteins, TAB2/3, resulted in the induction of the ovine FSHb promoter to equivalent levels as activin. A DN TAK1 also reduced activin induction [31] . These data indicate that the TAK1/p38 signaling pathway might also play an important role in activin responsiveness in gonadotrope cells.
Defining activin responsive regions on the FSHb promoter Activin responsive regions on the FSHb promoter were originally characterized as putative SBEs, although only one of these elements in the rodent promoter has been shown to directly bind Smad proteins [30, 33, 35] . Because the other elements do not bind Smads directly or bind them with low affinity, the focus shifted to defining what other transcription factors bind to these elements and whether these factors can interact with Smads to tether them to the promoter. To define these elements fully, it is important to determine whether they are necessary and sufficient for activin induction of FSHb gene expression using cis mutations in the FSHb promoter and tandem copies of the element linked to a heterologous promoter, respectively.
Smad regulation of FSHb gene expression via the S267 SBE A single consensus SBE at positions À267/À260 of the murine and À266/À259 of the rat FSHb promoter has been extensively characterized (Figure 2) [30, 33, 35] . Mutation of this element diminishes the response to activin [30] , although the response is not completely blocked, suggesting the presence of additional regulatory elements on the rodent promoter that are responsive to activin signaling. The overall evidence indicates that Smad2/3/4 bind to this consensus element. The DNA binding domains of recombinant Smad3/4 were reported to bind the À267 site [35] . Antibodies to Smad2/3/4 also alter complex formation on this region of the promoter in gel-shift assays using LbT2 nuclear extracts, suggesting their presence in the complexes [30, 33, 35] . Magnetic separation of proteins bound to a biotinylated FSHb oligonucleotide and DNA precipitation experiments also demonstrated binding of Smad2/3/4 to this element [30, 35] . Interestingly, this SBE is present only in rodent FSHb promoters, indicating that it might be involved in the species-specific sensitivity to Smad proteins. In support of this idea, addition of this element to the human FSHb promoter increased its responsiveness to activin and Smad3 overexpression [35] . It is possible that the consensus SBE in the murine and rat promoters plays a species-specific role in the rapid regulation of FSHb synthesis necessary in the short rodent estrous cycle.
Pbx/Prep and Ptx regulation of FSHb gene expression via the S120 and S54 elements
In silico scanning of the ovine FSHb promoter revealed many putative SBEs [14] . Mutation of a putative Smad half site at À134 in the ovine and the homologous À120 in the murine proximal promoter resulted in a substantial decrease in activin responsiveness (Figure 2) [36] . The TALE homeodomain proteins Pbx1 and Prep1 were found to bind to this element in vitro and in vivo [36] . Electrophoretic mobility shift assay (EMSA) demonstrated that Pbx1 and Prep1 recognized a CTGTCTATCCAA element encompassing the putative Smad half site on the ovine promoter. Chromatin immunoprecipitation experiments showed that both proteins were recruited to the murine proximal FSHb promoter. Pbx1 and Prep1 were also shown to interact with Smad2/3/4, and a Smad4 antibody disrupted a higher-order complex containing Pbx and Prep observed in EMSA [36] , whereas an antibody to Smad 2/3 caused a supershift [27] , suggesting that Smad proteins can be recruited to the proximal FSHb promoter indirectly via protein-protein interactions with Pbx/Prep. Corpuz et al. found that the À267 consensus SBE (which binds Smads directly) and the À120 Pbx/Prep site (which tethers Smads) were each sufficient to convey activin responsiveness when linked in tandem to a heterologous promoter [25] . By contrast, tandem copies of a Smad half site were not sufficient for induction by activin, indicating that highaffinity interactions additional to those provided by a Smad half site are required [25] . In addition to Pbx/Prep, Smads have also been shown to interact with Ptx [33, 37, 38] . Ptx binds to a paired-like homeodomain-binding site at position À54 of the rat and murine FSHb promoters (À65 of the human promoter) (Figure 2 ) [38, 39] to coordinate basal expression and activin induction. Thus, these studies provide evidence that activin signaling to the FSHb promoter involves the transcription factors, Pbx/Prep and Ptx, which tether Smad proteins to the promoter.
[ ( F i g u r e _ 2 ) T D $ F I G ]
FoxL2 regulation of FSHb gene expression via sites at S350, S208, S153 and S106 Mutation of an additional putative Smad half site (À167 and À153 in the ovine and murine promoters, respectively) resulted in a substantial decrease in activin responsiveness ( Figure 2 ) [36] . Smad regulation of this element was suggested by experiments showing that FSHb induction by Smad3 overexpression was reduced by mutations in the murine À153 element [25, 27] . However, many attempts to demonstrate Smad binding directly to this site were unsuccessful, making it unclear whether this site represented a bona fide SBE or an element that binds additional transcription factors that might coordinate with Smad proteins to elicit an activin response.
Further analysis of the FSHb promoter demonstrated that FoxL2, a member of the forkhead family of transcription factors, was essential for activin responsiveness. FoxL2 was previously reported to be expressed in gonadotrope cells and to regulate transcription of the follistatin and GnRH receptor genes [40] [41] [42] . FoxL2-mediated induction of the follistatin and GnRH receptor genes was dependent on adjacent Smad sites, and FoxL2 functioned in complex with Smad3. Interestingly, blepharophimosis ptosis epicanthus inversus syndrome (BPES), an autosomal dominant disorder, is characterized by distinctive eyelid abnormalities that result from a mutation in the FoxL2 gene. Two clinical subtypes have been described, and type I is associated with premature ovarian failure [43] .
Our recent studies have shown that FoxL2 binds the À153 element in the murine FSHb promoter and the homologous À164 element in the human promoter ( Figure 2 ) [25] . The homologous porcine À164 site was also reported to bind FoxL2 with a much higher affinity than the murine or human promoters due to a single basepair substitution [44] . Mutation of the putative Smad half site (AGAC) in this element disrupts FoxL2 binding, indicating that these bases play an important role in the FoxL2 binding element. In addition to the proximal À153 site, the murine and human FSHb promoters contain other FoxL2 binding sites. Elements at À350 and À208 in the murine promoter and the equivalent À223 site in the human promoter bind FoxL2 (Figure 2 ) [25] . These upstream sites bind FoxL2 with higher affinity and, interestingly, lack an overlapping Smad half-site sequence. Furthermore, in contrast to the follistatin gene, an adjacent Smad half-site at À355 does not contribute to FoxL2 binding or activin induction of the murine FSHb gene. Taken together, these results indicate that the function of FoxL2 is not solely to recruit Smads to the promoter.
Somewhat surprisingly, the FoxL2 elements were not on their own sufficient to convey activin responsiveness. However, these elements were necessary for the response, as cis mutation of any of these elements rendered the FSHb promoter unresponsive to activin, even in the presence of intact SBEs. Induction of the murine promoter by Smad3 overexpression was also diminished by mutations in the FoxL2 sites, implying protein-protein interactions between FoxL2 and Smad proteins. Although the human promoter is not responsive to Smad overexpression, it still requires the FoxL2 sites for induction by activin [25] , suggesting that activin directly activates FoxL2.
Analysis of the murine FSHb promoter also revealed two other activin responsive regions at À139 and À106 (Figure 2 ) [27] , which were originally identified as a steroid hormone response element [24] and an AP-1 element [45] . FoxL2 was reported by Corpuz et al. [25] to bind to an extended element ( Figure 2 ) compared with the previously reported 7 bp forkhead element [46] , which is in agreement with FoxL2 binding as a dimer [44] . In this case, the À153 element would extend to À138 and might partially explain the involvement of the previously identified À139 hormone response element in activin signaling. Interestingly, the AP-1 binding site at À120 in the ovine promoter was shown to mediate GnRH response in cell culture model systems [45, 47] but was reported to be dispensable for activin responsiveness. By contrast, the corresponding À106 element in the murine promoter was reported to play a role in activin induction, although it was not established which proteins mediated this effect [27] . More recently, Lamba et al. identified the À106 site as a FoxL2 binding site, although different base pairs were mutated [44] . Because the FoxL2 binding site in the reverse orientation in the murine promoter (CTAAACAA) is adjacent to the À120 site (discussed previously as a Pbx binding element), it is possible that specific cis mutations interfere with the binding of FoxL2 and/or Pbx/Prep to this region. The role of the À106 element in GnRH signaling might be a result of the necessity for endogenous activin in GnRH responsiveness on the FSHb gene [14, 29] . 9 Runx regulation of murine FSHb gene expression via an element at S159 Su et al. demonstrated that disruption of a sequence juxtaposed to the À167 activin response site within the ovine FSHb promoter caused severe dysregulation of basal expression and transcriptional regulation by activin in LbT2 cells and in vivo [48] . In silico analysis indicated that this sequence could be a putative binding site for the Runx family of transcription factors. Recently, we have demonstrated that Runx1-3 are expressed in gonadotrope cells and that overexpression of Runx proteins blocks activin induction of the murine, ovine and human FSHb promoters [49] , indicating that repression by Runx is conserved among these mammalian species. We also identified a Runx cis-regulatory element at À159 in the murine FSHb promoter next to the À153 site essential for activin responsiveness (Figure 2) . Furthermore, we showed that the À159 site was necessary for Runx2 binding to the FSHb promoter and essential for Runx2 repression of activin induction [49] . The modulation of activin responsiveness by Runx proteins highlights how FSHb expression levels are tightly regulated in gonadotrope cells and provides an additional candidate for negative feedback of activin action. Given the complexity of TGFb family signaling pathways characterized in a variety of cell types, it is probable that many additional regulators of activin signal transduction in gonadotrope cells await discovery.
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Summary
As this review discusses, activin signaling in pituitary gonadotrope cells involves an impressive array of transcription factors in the induction of FSHb transcription in mammalian species (Figure 3) . It is also evident that comprehension of activin signal transduction to the FSHb promoter is still at a relatively rudimentary level. Many important players have been identified, but how they coordinate with each other to elicit a transcriptional response remains to be determined (Box 2). For activin induction of rodent FSHb promoters, Smad proteins play a crucial role in relaying the activin signal through direct actions on the DNA, as well as being recruited to the promoter via interactions with other proteins such as Pbx/Prep and potentially Ptx and FoxL2 (Figure 3 ). FoxL2 binding to the FSHb promoter is also essential for activin responsiveness. For the human or ovine genes, it is still not clear whether Smad proteins are required for activin signaling. Moreover, the full panoply of factors and cofactors that provide positive or negative feedback to the activin signal awaits further investigation. Activin has been recently reported to interact synergistically with both GnRH and steroid hormone signaling pathways to upregulate FSHb gene expression (recently reviewed in [50] ). In addition, a negative regulator of activin induction, Runx, was recently described (Figure 3 ) [49] . However, further research is needed to comprehend how activin signaling integrates into the complex network of hormonal signaling pathways activated in the gonadotrope cell during the estrous cycle. Such research might lead to new treatments for the infertility or subfertility that can result from malfunction in FSH production, as well as the development of novel contraceptive methods. 
